// company-profile

Liminatus Pharma, Inc. Insider Trading

LIMN

Every SEC Form 4 insider trading filing for Liminatus Pharma, Inc. (LIMN) — open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC.

ExchangeNasdaqSectorBiological Products, (No Diagnostic Substances)Inc.DEFilings1Insiders2
// api This Liminatus Pharma, Inc. insider-trading data is served live by the Form4API insider trading API. Get the same data via API.

// activity-summary

Mixed insider activity over the last 30 days: 0 purchases and 0 sales (0 transactions total).

// 90-day insight

Over the last 90 days, Liminatus Pharma, Inc. insiders filed 1 Form 4 transaction, none of which were open-market purchases or sales.

  • Most active insider: Valetudo Therapeutics LLC with 1 transaction totaling $0.

Activity skews bullish — buys outpace sales.

Institutional Ownership

Top 13F-HR holders of Liminatus Pharma, Inc. as of 2026-03-31

— stable
Total reported AUM
$184,868
QoQ change
-0.3%
Reporting period
2026-03-31
#1
CITADEL ADVISORS LLC
CIK 1423053
$116,465
678K shares
#2
GEODE CAPITAL MANAGEMENT, LLC
CIK 1214717
$18,639
108K shares
#3
JANE STREET GROUP, LLC
CIK 1595888
$10,335
60K shares

Data source: quarterly 13F-HR filings — institutional holders report positions within 45 days of quarter end. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →

Insider Transactions

Sourced from SEC EDGAR Form 4 filings. Updated hourly.

DateInsiderCompanyTypeSharesPriceValue
Jun 24, 2026Valetudo Therapeutics LLCLIMN
J
4,373,603